F-1/A: IceCure Medical Seeks $16.5 Million in Best Efforts Offering to Advance Cryoablation Technology

IceCure Medical Ltd. is launching a best efforts offering of up to 22,222,222 ordinary shares and warrants, aiming to raise approximately $16.5 million for business development, R&D, and general corporate purposes.

Summary

• IceCure Medical Ltd. is offering up to 22,222,222 ordinary shares along with warrants to purchase an equal number of ordinary shares.
• The offering also includes pre-funded warrants for purchasers whose ownership would exceed certain thresholds.
• The assumed combined public offering price is $0.81 per ordinary share and accompanying warrant, but the actual price will be negotiated.
• Each warrant will be exercisable for one ordinary share at an assumed exercise price between $0.81 and $0.89, expiring five years from the issuance date.
• The company intends to use the net proceeds of approximately $16.5 million for business development, marketing, research and development, and general corporate purposes.
• Maxim Group LLC is the lead placement agent, and Roth Capital Partners LLC is the co-placement agent for the offering.
• The offering is on a best efforts basis, meaning there's no guarantee all securities will be sold.
• The company recently submitted data to the FDA for marketing authorization to treat early-stage breast cancer, with a decision expected in the first quarter of 2025.
• For the nine months period ended September 30, 2024, IceCure generated $2.4 million in revenues.
• As of September 30, 2024, IceCure had approximately $10.67 million in cash and cash equivalents, including short-term deposits.

Sentiment

Score: 6

Explanation: The document is primarily factual, outlining the terms of the offering and providing some company information. The sentiment is neutral, with a slight positive leaning due to the potential for growth and FDA approval.

Positives

• The company has a pending FDA decision for its ProSense system for early-stage breast cancer treatment, with a majority of the advisory panel voting favorably.
• The company has existing FDA marketing authorization for the IceCure family of products for various indications.
• The company has engaged experienced placement agents to manage the offering.
• The warrants are exercisable immediately, providing potential upside for investors.
• The company intends to use the net proceeds from this offering for business development and marketing activities, research and development and general and corporate purposes.

Negatives

• The offering is on a best efforts basis, meaning the company may not raise the full $16.5 million.
• There is no established public trading market for the warrants.
• The company is an emerging growth company and a foreign private issuer, which means reduced reporting requirements.
• The company has a history of losses and may need to raise additional capital in the future.
• The company's principal executive offices, most of its research and development activities and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel.

Risks

• The market price of the company's ordinary shares may be highly volatile.
• Future sales of ordinary shares could depress the market price.
• Management has broad discretion as to the use of proceeds.
• Purchasers will incur immediate and substantial dilution in the book value of their investment.
• The company may be unable to comply with Nasdaq continued listing requirements.
• Non-U.S. governments often impose strict price controls, which may adversely affect future profitability.
• The company's operations are subject to political, economic, and military instability in Israel.

Future Outlook

The company anticipates an FDA decision on its marketing authorization request for ProSense in the first quarter of 2025 and intends to use the net proceeds from this offering for business development and marketing activities, research and development and general and corporate purposes.

Industry Context

IceCure Medical operates in the medical device industry, specifically focusing on cryoablation technology. This offering aims to support the company's growth and commercialization efforts in a competitive market.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• Without more information, it's difficult to assess IceCure's performance against global benchmarks.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from increased investment in R&D and business development.
• Customers may benefit from improved products and services.
• Suppliers may see increased demand for their products.
• Creditors may be impacted by changes in the company's financial condition.

Next Steps

• The company will negotiate the final offering price with investors.
• The company awaits the FDA's decision on the ProSense marketing authorization request.
• The company will execute its business development and marketing plans using the proceeds from the offering.

Key Dates

Keywords

IceCure Medical, cryoablation, ordinary shares, warrants, best efforts offering, ProSense, FDA, breast cancer, medical device, capital raise